Bubs Australia Limited (ASX:BUB)
Australia
· Delayed Price · Currency is AUD | Market Cap | 98.35M |
| Revenue (ttm) | 109.51M |
| Net Income (ttm) | 3.78M |
| Shares Out | 894.13M |
| EPS (ttm) | 0.00 |
| PE Ratio | 25.97 |
| Forward PE | 39.15 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 3,200 |
| Average Volume | 911,020 |
| Open | 0.110 |
| Previous Close | 0.110 |
| Day's Range | 0.110 - 0.110 |
| 52-Week Range | 0.097 - 0.190 |
| Beta | 0.20 |
| RSI | 53.35 |
| Earnings Date | Feb 26, 2026 |
About Bubs Australia
Bubs Australia Limited, together with its subsidiaries, manufactures and sell infant and adult chilled and powdered goat dairy products in Australia, China, the United States, and internationally. The company offers goat and cow milk infant formulas, goat milk powder products for adults, and fresh dairy products. It also provides organic baby food, cereals, toddler snacks, and chilled goat milk. In addition, the company holds IP and trademarks. It sells its products under the Bubs and Caprilac brands. The company exports its products to China, ... [Read more]
Financial Performance
Financial StatementsNews
Bubs Australia Transcript: Status update
A new executive team is driving disciplined global growth in premium infant nutrition, with upgraded FY26 revenue guidance and strong brand positioning in Australia, China, and the U.S. The company is expanding into new markets, investing in supply chain resilience, and shifting marketing to build long-term brand equity with a capital-light, agile model.
BUBS Australia Ltd (ASX:BUB) (Q1 2026) Earnings Call Highlights: Strong US Growth and Positive ...
BUBS Australia Ltd (ASX:BUB) (Q1 2026) Earnings Call Highlights: Strong US Growth and Positive EBITDA Amid Operational Challenges
Half Year 2026 Bubs Australia Ltd Earnings Call Transcript
Half Year 2026 Bubs Australia Ltd Earnings Call Transcript
Bubs Australia Earnings Call Transcript: H1 2026
Revenue rose 14% year-over-year, led by U.S. expansion and strong China performance. Gross margin exceeded 50%, and FY26 revenue is projected to grow 22%-27%. Key risks include currency volatility, tariffs, and regulatory challenges.
Bubs Australia Transcript: AGM 2025
The meeting reviewed strong FY 2025 results, with 23% revenue growth and a focus on U.S. market expansion. Strategic priorities include FDA approval, inventory investment, and a 2030 growth plan. Shareholders voted on key resolutions, and leadership addressed questions on China, tariffs, and future opportunities.
Bubs Australia Earnings Call Transcript: H2 2025
Revenue grew 29% to $102.5M, gross margin hit 48%, and positive operating cash flow reached $6.1M, driven by strong U.S. growth and disciplined working capital. Inventory rebuild and margin normalization are expected in FY 2026 as the company invests in marketing and expansion.
Bubs Australia Earnings Call Transcript: H1 2025
Delivered first-ever net profit after tax of AUD 3.6 million and 23% revenue growth, driven by strong U.S. and China performance. Gross margin reached 50%, with positive EBITDA and improved cash flow. Confident in FDA approval and permanent U.S. market access in 2025.
Bubs Australia Transcript: AGM 2024
The meeting highlighted strong revenue and margin growth across all regions, successful execution of the first year of a three-year turnaround plan, and a clear path to profitability in FY25. Shareholders' questions focused on margins, cash flow, and governance, with all resolutions put to poll.
Half Year 2024 Bubs Australia Ltd Earnings Call Transcript
Half Year 2024 Bubs Australia Ltd Earnings Call Transcript
Bubs Australia Earnings Call Transcript: H2 2024
FY2024 saw 33% revenue growth to AUD 80 million, with strong gains in the US and China, improved gross margins, and reduced cash burn. FY2025 guidance targets 28% revenue growth, positive EBITDA, and continued international expansion.
Bubs Australia Earnings Call Transcript: H1 2024
Bubs Australia Transcript: AGM 2023
Bubs Australia Earnings Call Transcript: H2 2023
Bubs Australia Transcript: Investor Update
Bubs Australia Transcript: AGM 2022
Bubs Australia Earnings Call Transcript: H2 2022
Bubs Australia shares surge on infant formula supply deal with Walmart
Shares of Bubs Australia jumped on Thursday after the company signed a deal to supply its infant formula products to U.S. retail giant Walmart amid a baby food shortage in the world's largest economy.